Our FACS, scRNAseq, and antibody blocking data indicated that intratumoral administration of LNP-pE285K-mAb markedly enhanced the infiltration of immune cells, including B cells, B-like cells, IFIT+_BCs, CD4+ T, CD8+ T, and NKT cells, while concurrently reducing the infiltration of tumor-associated macrophages, Rest_BCs, and neutrophils in MC38-p53KO/E285K subcutaneous tumors. This evidence concerns the gene CD4 and neoplasm.